[Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder].

Date publication

juillet 2020

Journal

Journal francais d'ophtalmologie

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Osswald D, De Seze J, Collongues N, Speeg-Schatz C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32631694

Résumé

Neuromyelitis optica spectrum disorder (NMO-SD) has been recognized for the past decade. Biomarkers such as anti-Aquaporin 4 antibodies (AQP4) and anti-Myelin Oligodendrocyte Glycoprotein (MOG) have been able to classify NMO-SD into several groups.

Mots clés

Anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibodies, Anti-aquaporin 4 (AQP4) antibodies, Anticorps anti-Myelin Oligodendrocyte Glycoprotein (MOG), Anticorps anti-aquaporines 4 (AQP4), NMO-SD, Neuro-ophtalmologie, Neuro-ophthalmology, Neuromyelitis optica, Neuromyélite optique

Référence

J Fr Ophtalmol. 2020 Jul 3;: